Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Advances In The Management Of Metastatic Breast Cancer: Options Beyond First-line Chemotherapy.
J. Ayoub, S. Verma, S. Verma
Published 2012 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
This article provides an overview of recent advances in chemotherapy that may be used for the treatment of patients with locally advanced or metastatic breast cancer (MBC). Key phase ii and iii trial data for eribulin mesylate, ixabepilone, and nab-paclitaxel, published since 2006, are discussed on the basis of recency, depth, and quality.Eribulin mesylate is the first monotherapy to significantly increase overall survival in patients with pretreated MBC, but nab-paclitaxel offers a novel and safer mode of delivery in comparison with standard taxanes. By contrast, the use of ixabepilone will be limited for now, until the associated neurotoxicity can be better managed. Alongside a brief overview of the other major chemotherapies currently in use, we have aimed to provide a Canadian context for how these novel agents may be integrated into clinical practice.
This paper references
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
J. Blum (1999)
Facts and controversies in the treatment of metastatic breast cancer
C Bernard – Marty (2004)
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
W. Gradishar (2009)
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
L. Zelek (2001)
Ixempra (Ixabepilone) Prescribing Information
Bristol–Myers Squibb (2010)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
F. Cardoso (2010)
Management of the
M. Martin (2005)
Ixabepilone, a novel epothilone analog in the treatment of breast cancer.
X. Pivot (2008)
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer.
M. Degardin (1994)
Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives.
N. E. El Saghir (2011)
Correspondence to: Shailendra Verma, The Ottawa Hospital Cancer Centre, 501 Smyth Road
Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence
F. Lee (2011)
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
H. Roché (2007)
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
N. Ibrahim (2005)
Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
J. Chirgwin (2011)
Multicenter, phase ii study of capecitabine in paclitaxel-refractory metastatic breast carcinoma patients
Jl Blum (2001)
S. North (1971)
The Ottawa Hospital Cancer Centre
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
P. Reichardt (2003)
Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
C. Zielinski (2010)
Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Alvaro Moreno-Aspitia (2009)
Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts.
F. Lee (2006)
Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
P. Vishnu (2011)
A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial
S. Moulder (2009)
Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.
I. Ringel (1991)
Chemotherapy for metastatic breast cancer.
S. Barni (2005)
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
J. O'Shaughnessy (2002)
Navelbine (Vinorelbine Tartrate) Injection [product monograph]
Pierre Fabre (2005)
Ixabepilone for the treatment of solid tumors: a review of clinical data.
N. Denduluri (2008)
Therapeutic options for metastatic breast cancer.
P. Morris (2009)
Treatment options for breast cancer resistant to anthracycline and taxane.
A. Moreno-Aspitia (2009)
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
E. Bajetta (2005)
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
T. Burzykowski (2008)
Phase ii trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer [abstract 1075
MA Danso (2012)
BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
F. Lee (2001)
Triple negative breast cancer: epidemiology and management options
S Dawood (2010)
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
G. Hortobágyi (2010)
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
V. Roy (2009)
Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?
J. T. Ribeiro (2012)
Invasive breast cancer: clinical practice guidelines in oncology
Rw Carlson (2011)
Ixempra (Ixabepilone) Prescribing Information
Myers Bristol (2010)
therapy for women with advanced breast cancer (bc)
In the end what matters most? A review of clinical endpoints in advanced breast cancer.
S. Verma (2011)
Role of liposomal anthracyclines in breast cancer.
V. Lorusso (2007)
Clinical and pharmacokinetic study of ixabepilone (ixa) plus epirubicin (epi) as
THE MANAGEMENT OF ADVANCED BREAST CANCER
M. Baum (1980)
Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties.
K. Gerth (1996)
Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
M. Danso (2008)
Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
D. Talbot (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC)
B. Somer (2007)
Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
Y. Yamamoto (2011)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC)
Global cancer rates could increase by 50% to 15 million by 2020 [press release]. Geneva , Switzerland: who; 2003. [Available online at: http:// www.who.int/mediacentre/news/releases
Triple negative breast cancer: epidemiology and management options. Drugs 2010;70:2247–58
S. Dawood (2010)
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
M. Stockler (2011)
Promotion of microtubule assembly in vitro by taxol
PETER B. Schiff (1979)
Third consensus on medical treatment of metastatic breast cancer
D. Berthold (2006)
Facts and controversies in systemic treatment of metastatic breast cancer.
C. Bernard-Marty (2004)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
E. Thomas (2007)
International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
O. Pagani (2010)
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
D. Nyman (2005)
Impact of chemotherapy beyond the first line in patients with metastatic breast cancer
A. Dufresne (2007)
Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
G. Gasparini (1994)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
J. Cortés (2011)
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
J. Sparano (2010)
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
E. Perez (2007)
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
J. Oshaughnessy (2001)
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
L. Vahdat (2009)
Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with Current OnCOlOgy—VOlume 19
Ks Albain (2012)
Navelbine (Vinorelbine Tartrate) Injection [product monograph
Pierre Fabre Pharma Canada (2005)
Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
S. Goodin (2008)
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
T. Sørlie (2004)
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
K. Possinger (1999)
Platinum-based chemotherapy in metastatic breast cancer: current status.
M. Decatris (2004)
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
E. Thomas (2007)
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
W. Dean-Colomb (2008)
Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial
M. Blackstein (2002)
Ixabepilone development across the breast cancer continuum: a paradigm shift
N. Ibrahim (2010)
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
E. Rivera (2010)
on behalf of the esmo Guidelines Working Group. Locally recurrent or metastatic breast cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up
F Cardoso (2010)
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
G. Sledge (2003)
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
J. Low (2005)
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
M. Martín (2007)
Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04-012)
B. Mirtsching (2008)
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
C. Bunnell (2008)
Phase II trial of weekly nab ( nanoparticle albumin-bound )-paclitaxel ( nab-paclitaxel ) ( Abraxane ) in combination with gemcitabine in patients with metastatic breast cancer ( N 0531 )
V. Roy (2009)
Available online at: http://www.asco. org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view &confID=55&abstractID=35599
J Clin Oncol
The Place for Eribulin in the Treatment of Metastatic Breast Cancer
W. Gradishar (2011)
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
D. M. Bollag (1995)
Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
V. Valero (2003)
E-mail: firstname.lastname@example.org * Hematology–Oncology Service
Are anthracycline-taxane regimens the new standard of care in the treatment of breast cancer?
V Valero (2003)
Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC). metastatic breast cancer and prior anthracycline treatment
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
A. Seidman (2008)
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
P. Fumoleau (2004)
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
J. Cortés (2010)
Phase ii trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel: abx) + capecitabine (xel) in first line treatment of metastatic breast cancer (mbc) [abstract 1053]
Bg Somer (2007)
The Binding Mode of Epothilone A on α,ß-Tubulin by Electron Crystallography
J. Nettles (2004)
Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients
J. Blum (2001)
Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.
M. Martín (2011)
Clinical and pharmacokinetic study of ixabepilone (ixa) plus epirubicin (epi) as AYOUB et al
L Gianni (2012)
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
M. Jordan (2005)
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Joanne L. Blum (2007)
Castiglione M on behalf of the esmo Guidelines Working Group. Locally recurrent or metastatic breast cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up
F Cardoso (2010)
This paper is referenced by
Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
T. Gamucci (2014)
Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients
J. Smith (2013)
Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
S. Saji (2013)
The Effects of Anthracycline/Taxane Adjuvant Chemotherapy and Resistance Exercise on Body Composition, Muscle Strength, Quality of Life and Fatigue in Breast Cancer Survivors
R. Lal (2016)
Breast cancer metastatic dormancy and emergence, a role for adjuvant statin therapy
Colin H. Beckwitt (2018)
Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
M. Hattori (2017)
Investigating the effects of CSF-1R and PI3Kdelta inhibition on a breast cancer bone metastasis model
Carolina Salazar Arcila (2013)
O CANCRO DA MAMA METASTIZADO É CURÁVEL? A PROPÓSITO DE UM CASO CLÍNICO
Vânia Alexandra (2013)
Eribulin mesylate: A new therapeutic option for metastatic breast cancer
S. Aditya (2013)
Etirinotecan pegol for the treatment of breast cancer
E. López-Miranda (2016)
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
D. Tripathy (2019)
Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer.
Paweł Bieniasz-Krzywiec (2019)
Individualizing treatment to optimize survival outcomes in breast cancer.
E. Perez (2013)
Why Are Canada ’ s OECD Numbers Different From Those in CIHI and Statistics Canada Reports ?
Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
V. Lorusso (2020)
An innovative anti-cancer Chinese herbal formula exhibited multi-targeted efficacies in metastatic breast cancer mouse model
G. Yue (2018)
Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity
Loujin Houdaihed (2020)